share_log

Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.5

Benzinga ·  Nov 14, 2023 13:43

Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $2.8 to $2.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment